08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

MACI regulatory update

Vericel submitted a BLA to FDA for MACI to treat symptomatic knee cartilage defects in adults. Vericel (formerly Aastrom Biosciences Inc.) acquired the matrix-induced autologous chondrocyte implant from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France)...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Aastrom sales and marketing update

EMA said Aastrom's matrix-induced autologous chondrocyte implant ( MACI) manufacturing site in Denmark has been closed. The agency added that it has been working with Aastrom to ensure patients under MACI treatment can complete their...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

Even as the major biotech indices creep toward new all-time highs, buysiders are hard-pressed to identify any major risks that could cause a downturn in the fourth quarter. At the same time, there are few...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Financial News

Aastrom financial update

Aastrom Biosciences Inc. (NASDAQ:ASTM), Ann Arbor, Mich.   Business: Gene/Cell therapy   Date announced: 2014-09-17   Note: Aastrom raised $5.2 million through the sale of 2.1 million shares at $2.55 to cover the overallotment from its Sept. 11...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Aastrom completes follow-on

Aastrom Biosciences Inc. (NASDAQ:ASTM), Ann Arbor, Mich.   Business: Gene/Cell therapy   Date completed: 2014-09-11   Type: Follow-on   Raised: $35 million   Shares: 13.7 million   Price: $2.55   Shares after offering: 21.7 million   Underwriter: Ladenburg Thalmann   Overallotment: 2.1 million   ...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Aastrom Biosciences Inc gene/cell therapy, dermatology news

Aastrom will discontinue manufacturing of MACI matrix-induced autologous chondrocyte implant in Denmark. Aastrom said its U.S. manufacturing facility will serve as the exclusive manufacturing facility for the Cell Therapy and Regenerative Medicine business, which...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Aastrom management update

Aastrom Biosciences Inc. (NASDAQ:ASTM), Ann Arbor, Mich.   Business: Gene/Cell therapy   Hired: Gerard Michel as CFO and VP of corporate development, formerly CFO and VP of corporate development of Biodel Inc.   ...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Aastrom, Sanofi deal

Gene/cell therapy company Aastrom completed its acquisition of Sanofi's Cell Therapy and Regenerative Medicine business for $6.5 million (see BioCentury, April 28). Aastrom Biosciences Inc. (NASDAQ:ASTM), Ann Arbor, Mich.   Sanofi (Euronext:SAN; NYSE:SNY), Paris, France   Business:...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Company News

Aastrom, Sanofi deal

Gene/cell therapy company Aastrom will acquire Sanofi's Cell Therapy and Regenerative Medicine business for $6.5 million. Aastrom will pay Sanofi $4 million in cash at closing, with the remainder payable in the form of a...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

Ixmyelocel-T: Phase IIb ongoing

Aastrom said an independent DSMB recommended continuation of the double-blind, placebo-controlled, U.S. Phase IIb ixCELL-DCM trial of ixmyelocel-T based on a planned interim review of unblinded safety data. ixCELL-DCM is evaluating 12-20 catheter-based intramyocardial injections...